1,795
Participants
Start Date
December 31, 2002
Primary Completion Date
October 31, 2009
Study Completion Date
October 31, 2009
Double-blind Abatacept
Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Day 1, 15, and 29.
Double-blind Placebo
Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
Open-label Abatacept
Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Every 28 days.
Local Institution, Decatur
Local Institution, Paradise
Local Institution, Phoenix
Local Institution, Tucson
Local Institution, San Francisco
Local Institution, Loveland
Local Institution, Hamden
Local Institution, Lake Worth
Local Institution, Largo
Local Institution, Blairsville
Local Institution, Chicago
Local Institution, Evansville
Local Institution, Indianapolis
Local Institution, Wichita
Local Institution, Louisville
Local Institution, New Orleans
Local Institution, Baltimore
Local Institution, Cumberland
Local Institution, Westminster
Local Institution, Boston
Local Institution, Grand Rapids
Local Institution, Royal Oak
Local Institution, Toms River
Local Institution, Los Alamos
Local Institution, New York
Local Institution, Durham
Local Institution, Hickory
Local Institution, Canton
Local Institution, Cleveland
Local Institution, Columbus
Local Institution, Elyria
Local Institution, Youngstown
Local Institution, Oklahoma City
Local Institution, Wyomissing
Local Institution, Columbia
Local Institution, Sioux Falls
Local Institution, Ducktown
Local Institution, Nashville
Local Institution, Richmond
Local Institution, Edmonds
Local Institution, Olympia
Local Institution, Tacoma
Local Institution, Menomonee Falls
Local Institution, Milwaukee
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY